Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

Completed · Phase 3 · Has a placebo group

Conditions studied: Benign Prostatic Hyperplasia (BPH)

In brief

This study will evaluate the safety and efficacy of a 2.5 mg dose of NX-1207 for the treatment of BPH (benign prostatic hyperplasia) as compared to placebo.

Key facts

Study ID
NCT00945490
Run by
Nymox Corporation
People needed
500
Starts
2009-05-01
Expected to finish
2014-05-01
Last updated by the study team
2017-03-10

Who can join

Age: 45 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.